Concord Biotech Ltd.
CONCORDBIO · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹541.15.
Piotroski F-score 4/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%13.5%
- ✓Low debt (D/E < 0.5)0.00x
- ✓Positive free cash flow
- ✕Revenue growth > 10%-24%
- ✕Earnings growing-37%
- ✓Net margin ≥ 10%24.7%
- ✓Current ratio > 1.57.39
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 41.57
- ✕Piotroski ≥ 74/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Healthy profit margin (24.7%).
- •Financially solid — Altman Z 41.57.
Threats
- •Earnings contracting year on year.
- •Trades ~51% above our estimated fair value.
About Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppr
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.